/
Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Mentions
1 mention · latest on 21 Sept 2026
See which tracked investors hold Indivior Pharmaceuticals, Inc. →Ownership and position changes on OwnershipTrace